Aromatase inhibitors (AIs) are widely used for the adjuvant treatment of postmenopausal breast cancer, generally prescribed for five years at the conclusion of surgery, chemotherapy and/or radiation treatment. This evidence concerns the gene CYP19A1 and breast cancer.